ATE511392T1 - Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit - Google Patents

Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit

Info

Publication number
ATE511392T1
ATE511392T1 AT08727550T AT08727550T ATE511392T1 AT E511392 T1 ATE511392 T1 AT E511392T1 AT 08727550 T AT08727550 T AT 08727550T AT 08727550 T AT08727550 T AT 08727550T AT E511392 T1 ATE511392 T1 AT E511392T1
Authority
AT
Austria
Prior art keywords
dosage forms
baclofen
methods
oral dosage
prodrug
Prior art date
Application number
AT08727550T
Other languages
English (en)
Inventor
David Kidney
Kenneth Cundy
Srikonda Sastry
Manshiu Leung
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Application granted granted Critical
Publication of ATE511392T1 publication Critical patent/ATE511392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08727550T 2007-01-11 2008-01-10 Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit ATE511392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88459807P 2007-01-11 2007-01-11
PCT/US2008/050796 WO2008086492A1 (en) 2007-01-11 2008-01-10 Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment

Publications (1)

Publication Number Publication Date
ATE511392T1 true ATE511392T1 (de) 2011-06-15

Family

ID=39432550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08727550T ATE511392T1 (de) 2007-01-11 2008-01-10 Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit

Country Status (8)

Country Link
US (1) US20080206332A1 (de)
EP (1) EP2117517B1 (de)
JP (1) JP2010515754A (de)
AT (1) ATE511392T1 (de)
CA (1) CA2674610C (de)
ES (1) ES2365574T3 (de)
TW (1) TWI369982B (de)
WO (1) WO2008086492A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670451A4 (de) * 2003-09-11 2009-10-21 Xenoport Inc Behandlung und/oder prävention von harninkontinenz mit prodrugs von gaba-analoga
BRPI0517227B8 (pt) 2004-11-04 2021-05-25 Xenoport Inc comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
EP2065038A1 (de) 2007-11-30 2009-06-03 Pharnext Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
WO2010064139A2 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
NZ594648A (en) * 2009-03-03 2013-12-20 Xenoport Inc Sustained release oral dosage forms of an r-baclofen prodrug
WO2010120370A2 (en) * 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
US9393241B2 (en) * 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (de) 2009-06-02 2010-12-22 Pharnext Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US20110071630A1 (en) 2009-09-10 2011-03-24 Boston Foundation For Sight Sodium channel blocker delivery system with scleral lens
US10786464B2 (en) 2009-11-03 2020-09-29 Lupin Limited Modified release formulation of lacosamide
WO2011079074A1 (en) * 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
WO2011101866A2 (en) 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd., A method of treating a disease condition susceptible to baclofen therapy
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
US8377956B2 (en) * 2010-03-01 2013-02-19 Xenoport, Inc. Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
BR112013013525A2 (pt) * 2010-12-02 2016-10-18 Ucb Pharma Gmbh formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
KR101918745B1 (ko) 2011-03-01 2018-11-15 파넥스트 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
EP2705842A1 (de) 2012-09-05 2014-03-12 Pharnext Therapeutische Ansätze zur Behandlung von Morbus Parkinson
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
CA2874737A1 (en) * 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Use of baclofen to treat insomnia
KR20150058159A (ko) 2012-07-18 2015-05-28 파넥스트 바클로펜 및 아캄프로세이트 기반 황반 변성 장애의 치료
EP2705841A1 (de) 2012-09-05 2014-03-12 Pharnext Kombinierungen aus Nootropikagenten zur Behandlung von kognitiven Dysfunktionen
EP2705843A1 (de) 2012-09-05 2014-03-12 Pharnext Therapeutische Ansätze zur Behandlung von Epilepsie und zugehöriger Erkrankungen durch Reduzierung der Epileptogenese
WO2014145195A1 (en) 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent
LT3003268T (lt) 2013-06-05 2018-12-10 Pharnext Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api)
CA2938361A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
BR112017017729A2 (pt) 2015-02-20 2018-04-10 Osmotica Kereskedelmi Es Szolgaltato Kft forma de dosagem oral de liberação controlada de agonista de receptor gaba
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
BR112018012870A2 (pt) 2015-12-30 2018-12-04 Adamas Pharmaceuticals Inc métodos e composições para o tratamento de transtornos relacionados à crise
US10799499B2 (en) 2016-02-05 2020-10-13 Pharnext Combinatorial therapies of neurological disorders
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
CA3061243C (en) 2017-04-24 2023-02-21 Pharnext Idalopirdine-based combinatorial therapies of alzheimer's disease
JP2021512174A (ja) 2018-01-29 2021-05-13 ファーネクストＰｈａｒｎｅｘｔ アセチルコリンエステラーゼ阻害剤療法に対する反応性を失った患者におけるアルツハイマー病のバクロフェン及びアカンプロセートを用いた療法
DK3760190T3 (da) 2019-07-03 2023-09-04 Alvogen Inc Tabletter af pregabalin med forlænget frigivelse, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
GB9308430D0 (en) * 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
DE60208065T2 (de) * 2001-08-09 2006-07-13 Eli Lilly And Co., Indianapolis Cyclohept'b! indolderivate als spla2-inhibitoren
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
EP1608357A4 (de) * 2003-03-31 2008-03-26 Xenoport Inc Behandlung oder prävention von hitzewallungen unter verwendung von prodrugs von gaba-analoga
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
KR20110097942A (ko) * 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP1670451A4 (de) * 2003-09-11 2009-10-21 Xenoport Inc Behandlung und/oder prävention von harninkontinenz mit prodrugs von gaba-analoga
BRPI0414481A (pt) * 2003-09-17 2006-11-14 Xenoport Inc métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
KR101096480B1 (ko) * 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
JP4927563B2 (ja) * 2003-12-30 2012-05-09 ゼノポート，インコーポレイティド アシルオキシアルキルカルバメートプロドラッグ及び中間体の合成
AU2005231433A1 (en) * 2004-04-02 2005-10-20 Impax Laboratories, Inc. Controlled release dosage for GABA receptor agonist
BRPI0517227B8 (pt) * 2004-11-04 2021-05-25 Xenoport Inc comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
WO2008011016A2 (en) * 2006-07-18 2008-01-24 Dynogen Pharmaceuticals, Inc. Treating gastroesophageal reflux disease with 5-ht3- and gaba receptor agonists
CN101616664A (zh) * 2006-11-14 2009-12-30 克塞诺波特公司 加巴喷丁和普加巴林的前药用于治疗耳鸣的应用
BRPI0720252A2 (pt) * 2006-12-08 2014-01-07 Xenoport Inc Uso de pró-fármacos de análogos de gaba para tratar doenças

Also Published As

Publication number Publication date
JP2010515754A (ja) 2010-05-13
WO2008086492A1 (en) 2008-07-17
TW200900054A (en) 2009-01-01
CA2674610C (en) 2013-06-18
EP2117517A1 (de) 2009-11-18
CA2674610A1 (en) 2008-07-17
ES2365574T3 (es) 2011-10-07
US20080206332A1 (en) 2008-08-28
TWI369982B (en) 2012-08-11
EP2117517B1 (de) 2011-06-01

Similar Documents

Publication Publication Date Title
ATE511392T1 (de) Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
EA201490949A1 (ru) Ингибиторы киназ
ATE469880T1 (de) Acyloxyalkylcarbamat-prodrugs von tranexansäure und anwendung
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
EA201490254A1 (ru) Комбинированное лечение гепатита с
CY1115381T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
WO2011056240A3 (en) Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CY1112770T1 (el) Αναστολεις κινασης και μεθοδοι χρησης τους
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties